Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | MMP8 | P22894 | 1/20 | 0.32 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.32 |
| ▸ | ZDHHC7 | Q9NXF8 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 2/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13167026 | 1.00 | CA1 (0.38) | CA1CA2SMN1; SMN2MMP8CA14 | |
| SCHEMBL20086668 | 0.80 | DGAT1 (0.34) | CA1CA2SMN1; SMN2MMP8 | |
| SCHEMBL10388981 | 0.80 | DGAT1 (0.34) | CA1CA2SMN1; SMN2MMP8 | |
| SCHEMBL15717665 | 0.79 | HTT (0.41) | CA1CA2SMN1; SMN2CA14ZDHHC7 | |
| SCHEMBL30219079 | 0.77 | CA1 (0.39) | CA1CA2SMN1; SMN2CA14ZDHHC7 | |
| SCHEMBL30931647 | 0.77 | CA1 (0.39) | CA1CA2SMN1; SMN2CA14ZDHHC7 | |
| SCHEMBL17236358 | 0.76 | SMN1; SMN2 (0.39) | CA1CA2SMN1; SMN2MMP8CA14 | |
| SCHEMBL5539779 | 0.76 | SMN1; SMN2 (0.39) | CA1CA2SMN1; SMN2MMP8CA14 | |
| SCHEMBL3044556 | 0.74 | DPP4 (0.38) | CA1CA2SMN1; SMN2MMP8CA14 | |
| SCHEMBL5366082 | 0.74 | DPP4 (0.38) | CA1CA2SMN1; SMN2MMP8CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120149683-A1 | SUBSTITUTED AMINOPIPERIDINES AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OF DIABETES | MERCK SHARP & DOHME LLC | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149683-A1 | SUBSTITUTED AMINOPIPERIDINES AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OF DIABETES | DPP4, DPP3, DPP7 | CA1 3188/4885CA2 726/4885SMN1; SMN2 4078/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.